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AbstractHemangiomas involving the spleen are rare and
seldom symptomatic. Treatment options for large
lesions usually consist of splenectomy, embolization, or
both. Antiangiogenic treatment has not been reported
previously as an effective alternative for this type of
lesion. We report our experience of successfully using
glucocorticoids in an infant with a large hemangioma of
the spleen.
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Introduction
Despite the fact that hemangiomas, or vascular tumors,
represent the most common primary neoplasm of the
spleen, less than 100 cases have been reported [1]. This
lesion is even less common in infants and young children
[2]. The patients are often asymptomatic, with many
diagnoses made at autopsy. The indications for surgical
intervention and other therapy remain unclear. There is
an increased risk of splenic injury and rupture, as well as
the possibility of developing hypersplenism or Kasa-
bach–Merritt syndrome, especially in larger lesions [3].
In addition there is the concern for malignancy, which
prompts splenectomy in most cases [4].
Antiangiogenic treatment has been primarily directed
at cutaneous or other lesions with a proliferative com-
ponent, also known as a ‘‘capillary’’ pattern [5]. The
majority of solid visceral hemangiomas are thought to
be resistant to antiangiogenic or steroid treatment,
therefore either expectant observation or surgery has
been recommended [2]. We present a case in which a
large splenic hemangioma regressed with antiangiogenic
therapy using glucocorticoids, avoiding a splenectomy.
This is the first such case reported to our knowledge.
Case
A 3-month-old boy presented with an asymptomatic left
abdominal mass that was discovered by his pediatrician
during a routine physical exam. The patient was other-
wise healthy and was the product of a full term,
uneventful pregnancy with no prenatal ultrasound
diagnosis of abdominal mass. Physical examination
revealed a firm, non-tender mass in the left side of the
abdomen without any bruit auscultated. There were no
cutaneous hemangiomas or vascular malformations
noted. A CT scan revealed a large, well-circumscribed
mass within the left upper quadrant that appeared to be
arising from the spleen. The mass was heterogeneous
with focal areas of high attenuation closely resembling
blood. A splenic ultrasound was performed which con-
firmed a large hypervascular mass within the lower pole
of the spleen. Doppler studies were indicative of active
blood flow within the mass. The lesion measured
5.7·4.8·5.3 cm3 in dimensions (Fig. 1 a, b). The splenic
vein was found to be enlarged. There were both hyper
and hypoechoic components to the lesion. The remain-
der of the spleen was separate from the mass and had
normal sonographic appearance. This was consistent
with the diagnosis of a splenic hemangioma (SH). The
infant had a mild anemia but was without any signs of
immunosuppression or thrombocytopenia. In order to
avoid splenectomy, we decided to treat him with oral
Prednisone (2 mg/kg/day) for antiangiogenic effect. No
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additional therapy was required for gastrointestinal
prophylaxis. He was monitored closely with serial
ultrasound and physical examination. Two weeks after
starting treatment, a repeat ultrasound showed the mass
to measure 4.0·4.3·4.2 cm, with decreased vascularity
of the splenic mass. Six weeks after steroid therapy the
mass was 3.0·3.5·3.2 cm3. The mass was also more
homogeneous and the hypoechoic areas were no longer
well visualized. Ten weeks after presentation the mass
measured 2.6·2.1·2.6 cm3 (Fig. 2) with much less vas-
cularity and virtually no hypoechoic areas. At 14 weeks,
the mass was barely detectable by ultrasonography. The
steroids were discontinued at this point.
The patient has done well clinically and had no ill
effects from the treatment. He is now over 3.5 years old,
with no evidence of recurrence of the lesion on repeat
ultrasound evaluation.
Discussion
Pediatric cases of SH are rare, with fewer than 20 cases
previously reported [2, 6]. This vascular lesion is detected
in adults more frequently, usually during the third to fifth
decade of life, or at autopsy [3, 7]. SH may be isolated or
associated with other skin, skeletal, or visceral vascular
Fig. 1 (a) Transverse
ultrasound image of the left
upper quadrant shows a
5–5.5 cm diameter solid mass
(large arrows). Focal hypo
echoic areas (small arrows) did
not completely show flow, and
may represent necrosis,
hemorrhage or stagnant flow
(b) Longitudinal image showing
that the mass (M) arises
exophytically off the inferior tip
of the spleen
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anomalies and may occur in patients with Klippel–
Trenaunay–Weber syndrome [8]. These lesions have been
reported in both Beckwith-Wiedemann and Turner syn-
dromes, as well as one of the various manifestations of
Proteus syndrome [9, 10]. The incidence of splenic vas-
cular malformations ranges from 0.03% to as high as
14% in autopsy series [1, 3, 7].
It is important to differentiate the vascular malfor-
mations from hemangiomas, as it is the latter which have
a proliferative component that may respond to anti
angiogenic treatments [11]. Vascular malformations
usually do not have a growth phase and, unless very
large, mostly remain asymptomatic. Hemangiomas are
the most common primary neoplasm of the spleen and
are composed of rapidly proliferating endothelium-lined
vascular channels filled with red blood cells [12]. The
lesions may be solitary or multiple. On gross examina-
tion it can be identified from the surface as a more in-
tensely blue/purple area, darker than the normal splenic
pulp [12]. The natural course of these lesions is usually
enlargement, possible slow involution, or rupture [3, 7].
The exact course for a given hemangioma is difficult to
predict. Larger tumors (>4 cm) are likely more prone to
rupture, either spontaneously or from minor trauma
than smaller ones, and may result in fatal hemorrhage
[3]. There has also been a reported rare association with
possible malignant transformation to angiosarcoma
with large SH, which leads most surgeons to favor a
splenectomy [4, 7].
The majority of patients are asymptomatic. Clinical
signs of pediatric cases of SH include an incidentally
discovered left upper quadrant mass, as was in our case.
Some patients may have early satiety or malaise from
the mass effect on the stomach. There have also been
reports of congestive heart failure, portal hypertension,
and gastrointestinal bleeding [2, 3, 7]. Thrombocytope-
nia, anemia, and consumptive coagulopathy (Kasabach–
Merritt syndrome) have been associated with larger SH
[2, 6].
SH are usually diagnosed by ultrasonography, com-
puted tomography, or magnetic resonance studies,
although reported features are variable [13, 14]. The le-
sions may be calcified, cystic, solid, or mixed [13]. So-
nographically, hemangiomas are frequently hyper echoic
with hypoechoic areas, may be well-marginated with
occasional calcifications or cysts depending on the size
[13, 15]. Our case demonstrated hypo echoic areas with
well defined margins. Doppler ultrasound may be help-
ful and demonstrate blood flow within the mass, which
was noted in our case as well [13].
Previously, it was suggested that SH may present with
severe hematologic symptoms or rupture, and splenec-
tomy was recommended for all [3]. Recent reviews in
adult patients report that asymptomatic patients with
small SH (<4 cm) have been managed conservatively
with observation, without rupture or other complica-
tions [7]. All pediatric cases, to our knowledge, have
been treated with partial or total splenectomy, both
approaches which have been successful [2, 6]. Partial
splenectomy maintains functional splenic tissue and
possibly mitigates the deleterious immunologic effects of
total splenectomy [12]. Our case would have been ideal
for a partial resection, as it was off the pole of the spleen.
There are also reports of using hand assisted laparos-
copy to treat these lesions with success [16].
The treatment for symptomatic or potentially disfig-
uring cutaneous hemangiomas during the proliferative
phase is antiangiogenic with corticosteroids or inter-
feron, although the exact mechanism remains unclear
[5]. Folkman demonstrated that hemangiomas secrete
Fig. 2 Longitudinal image of
the spleen after 10 weeks of
therapy shows substantial
decrease in the size, now
2–2.5 cm in diameter. (S spleen)
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angiogenic agents such as B-FGF which can be detected
in the urine, and these are reduced with anti angiogenic
therapy. Other drugs successfully used have been the
COX-2 inhibitors and Thalidomide [5, 11].
Review of the literature did not reveal any cases of
SH showing progressive regression with antiangiogenic
therapy. In our case, we decided to attempt therapy with
corticosteroids to avoid a splenectomy with its potential
for long term immunosuppression and possible over-
whelming sepsis. We had planned for a partial splenec-
tomy, in case our therapy failed. We used an initial
regimen of Prednisone 2 mg/kg/day. The lesion showed
regression after 2 weeks of treatment, which persisted
during and after the therapy. The steroids were weaned
during the 14 week period. This duration of therapy was
chosen after the mass had reduced in size and then the
steroids were tapered. Long term follow up is needed to
determine the efficacy of this treatment.
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